Importantly, targeting USP9X attenuates B cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance [111], a death process dependent on Bim [14]. The gene discussed is BCL2L11; the disease is B-cell acute lymphoblastic leukemia.